Growing the #antibiotics pipeline to address global need is essential yet requires new regulatory, policy & pricing pathways to create viable economic models for new #antibiotics, as CIDS India President Dr. Venkatasubramanian Ramasubramanian suggests. bit.ly/3TQwWM5

Thanks to all who worked to reintroduce the #PASTEURAct. This legislation + other steps to modernize reimbursement for newer #antibiotics are key to saving lives and our essential industry of innovators. Learn more: bit.ly/40Ss1Ml #AntimicrobialResistance #AMR

Thank you Donna E. Shalala Lilian Abbo and Dr. Mark McClellan for highlighting the complexities of #AMR and how it impacts patients while calling for the federal government to work quickly to change the marketplace dynamics. bit.ly/3JM9NGS #PASTEURAct #DISARMAct

As the threat of #AntibioticResistance continues to increase, these types of stories will become more common. We all need to work together to change the trajectory of #AMR. bit.ly/3XRGnNa

Outstanding article by Karen Weintraub and Adrianna Rodriguez on the current state of #antibiotics and what can be done to solve #AMR. One more way to ensure antibiotics are available is modernizing reimbursement to recognize the value of life-saving antibiotics. bit.ly/3ONvPM8

Proud to join this impressive group - Mark McClellan, MD, PhD, Lynn Filpi, Payal K. Patel & John H. Rex, MD - for an incredibly important Duke-Margolis webinar examining what can be done to advance #pandemic preparedness in the face of viral & bacterial threats. Register ⤵️ #AMR

There’s still time to register for tomorrow’s 1 pm Duke-Margolis webinar. I’ll join other experts to discuss the threat viral and bacterial infections pose for national security, global public health and the economy. Don’t miss it. Register here: bit.ly/3YLvdtM #AMR

Another big pharma cutting infectious disease R&D as viral and bacterial infections threaten national security and global health more than ever. Read about Janssen's plans: bit.ly/3OXn9li #AMR

Glad to be part of the important discussion during the Duke-Margolis #AMR webinar. The solution is complex & requires the involvement of the entire U.S. Gov’t & w/out legislative engagement there will be no progress. More about the solutions discussed: bit.ly/3sCpbQf

Thank you Laura Helbling for featuring my views on the Diagnosis Related Group (DRG) system & why #Medicare needs to modernize its approach & create a separate payment system that recognizes the value of novel, life-saving antibiotics. bit.ly/3EL4rbS #AntimicrobialResistance

Check out Dominique Mosbergen's The Wall Street Journal article on the business of #antibiotics. I'm proud of Paratek's success in a challenging marketplace. However, if we don't modernize today's reimbursement system, the innovation curve for antibiotics will continue to crater. bit.ly/3t97wjr

More #AMR funding is always good news however it's not enough to fix the industry. Gov’t must support a marketplace that incentivizes innovation & requires new regulatory, policy & reimbursement pathways to create viable access models for new #antibiotics. bit.ly/46l2xus

Insightful read from Andrew Jack of the Financial Times, examining how war is spreading disease and escalating #AMR globally. Government leaders must improve access to novel #antibiotics to help protect against this material threat. on.ft.com/47nSzsG

Lots to consider here as Bill Gates explains why 2024 could shape our world for years. Particularly intrigued by the potential of #AI as a vehicle to help combat #AMR. Read more about this research & other innovations shaping our world in the Gates Report: gatesnot.es/3NNvmIX

Looking forward to a robust discussion tomorrow (Jan. 18) as I join other industry leaders to preview the Biotechnology Innovation Organization CEO & Investor Conference & talk about how BIO’s 1:1 Partnering can help you make progress against your ‘24 business goals. Register for the webinar⤵️ #BIOCEO24

Congratulations Jonathan Light and Christopher Bostrom. I look forward to continuing to partner with you as we advance Paratek's growth strategy.

Disheartened to read about declining number of scientists w/ #AMR expertise in the AMR IndustryAlliance report. Public-private partnerships, such as the Paratek-BARDA partnership, are a way to support new research for innovative #antimicrobials. bit.ly/3SOS9FQ

Given mounting geopolitical tensions, we need to be more concerned about our country's #supplychain for critical medicines. To echo John F. Crowley, “The consequences of having critical manufacturing offshore are clear… we have to be prepared.” #antibiotics #biotech

Agree w/ experts on strengthening the #antibiotic pipeline by addressing market failures & boosting investments to ensure success across the value chain, incl. commercialization needs. Encouraged by this & other strategies to combat #AMR from GLG on AMR. bit.ly/3PU6oIZ

Strong public-private partnerships are critical for national security & the significant impact of leveraging private sector expertise in antimicrobials to advance preparedness and response capabilities is clear. Paratek looks forward to being a part of this effort. #PublicHealth